secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARDELYX, INC. (ARDX)
CIK:        0001437402
Form:       8-K
Filed at:   2026-02-19T23:59:59+00:00
Accession:  0001437402-26-000012
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ardelyx reports 2025 revenue $407.3M; IBSRELA up 73% to $274.2M; guides 2026 higher
--------------------------------------------------------------------------------

- IBSRELA revenue $274.2M in 2025 (+73% YoY); Q4 $86.6M (+61% YoY).
- XPHOZAH revenue $103.6M in 2025; 2026 guidance $110-120M.
- Total 2025 revenue $407.3M; net loss $61.6M ($0.26 loss per share).
- Cash $264.7M at Dec 31, 2025; fully capitalised for current plans.
- Phase 3 ACCEL trial for tenapanor in CIC dosed first patient; topline H2 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1437402/000143740226000012/0001437402-26-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1437402/000143740226000012/ardx-20260219.htm
  HTML page:      https://secwatch.observer/filing/0001437402-26-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer